Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr
virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in
the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in
the HL patient and compare to existing historical control data.